PCOS Treatment in India: A Clinical Reference Guide

This is a clinical-reference overview for a treating physician or hospital pharmacy stocking decision, not a self-treatment guide. It covers diagnostic criteria, the evidence behind each drug class, where combination therapy outperforms either drug alone, and what that means for what a hospital pharmacy needs on its shelf.

What are the Rotterdam criteria for diagnosing PCOS?

A PCOS diagnosis in an adult requires at least two of three features: oligo-ovulation or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. Meeting two of three is sufficient; a patient does not need all three findings to carry the diagnosis.

The 2023 International Evidence-based PCOS Guideline, published in Human Reproduction and endorsed by professional bodies worldwide, updated the 2018 framework to allow anti-Müllerian hormone (AMH) testing as an alternative to ultrasound in adults, and simplified diagnosis further when irregular cycles and hyperandrogenism are both already present, in which case imaging isn't required at all.

Which drug class treats which PCOS feature?

Combined oral contraceptive pills (COCPs) are first-line for menstrual irregularity and hyperandrogenic symptoms like acne and hirsutism in a patient not currently seeking pregnancy. They work by suppressing ovarian androgen production and increasing sex-hormone-binding globulin, which lowers free testosterone.

Metformin targets the metabolic and insulin-resistance side of the syndrome rather than the hormonal side. The 2023 guideline recommends metformin in adults with PCOS and a BMI of 25 kg/m² or higher, primarily to improve insulin sensitivity, glucose handling and lipid profile, not as a first-line fertility or cycle-regulation drug on its own.

Does metformin or the combined pill work better, or is combination therapy the actual answer?

Neither drug alone outperforms the other across every outcome; each targets a different mechanism, and a 2019 systematic review with meta-analysis found the combined pill more effective for hirsutism and cycle regularity while metformin performed better on metabolic markers, with combination therapy outperforming either single agent on several measures.

The COMET-PCOS randomised trial, published in PLOS Medicine, directly compared low-dose combined pill, extended-release metformin, and both together over 24 weeks in women with hyperandrogenic PCOS and obesity, finding measurable differences in metabolic syndrome outcomes across arms. This is exactly the kind of head-to-head evidence a prescribing decision should rest on rather than habit or whichever drug a rep last pushed.

What about anti-androgens like spironolactone?

Anti-androgens such as spironolactone are typically added when hirsutism or acne doesn't adequately respond to 6 or more months of a combined pill alone, never as monotherapy in a patient who could become pregnant, because of teratogenic risk to a male fetus. They are an add-on class, not a substitute for hormonal cycle control, and effective contraception is required alongside them for exactly this reason.

This sequencing, pill first, anti-androgen added later if needed, is standard across the international guideline framework for PCOS India prescribing and is a common area where a stocking gap in a hospital pharmacy forces a second visit or an outside prescription fill after the initial consult already happened.

What if the patient is trying to conceive?

Letrozole is the first-line ovulation-induction agent for PCOS-related infertility, ahead of clomiphene citrate, based on trial evidence of higher live-birth rates with letrozole in this population, a finding that shifted guidance away from clomiphene as the default. Metformin may be added as an adjunct, particularly with insulin resistance, but doesn't substitute for an ovulation-induction agent.

Combined pills are explicitly not used in this scenario since they suppress ovulation rather than induce it, an obvious but frequently confused point when a PCOS India patient is switched between a symptom-control phase and a fertility-seeking phase of care.

What lifestyle evidence actually supports drug therapy?

Weight management of even 5 to 10% of body weight measurably improves ovulatory function and metabolic markers in PCOS, and guideline bodies consistently list lifestyle intervention alongside, not instead of, drug therapy for patients with an elevated BMI. Neither replaces the other; they're additive.

This is not a call to defer drug therapy while a patient attempts lifestyle change alone. The 2023 international guideline frames lifestyle and pharmacological management as running concurrently, particularly for the metabolic features where metformin's benefit compounds with weight change rather than being replaced by it.

What does inconsistent drug availability actually cost a PCOS patient?

PCOS India management is a chronic condition managed over months to years, often with a combined pill, metformin, and an anti-androgen running concurrently or in sequence. A hospital pharmacy that stocks the pill but not metformin, or stocks neither reliably, pushes the patient toward filling different parts of one prescription at different outside chemists.

That fragmentation isn't just an inconvenience. A patient managing three drug classes across two or three outside pharmacies is a patient the treating hospital loses visibility on for adherence and follow-up, and one whose refill revenue leaves the building entirely. Our managed hospital pharmacy services piece covers how a chronic, multi-drug-class condition like this is exactly where reliable in-house stocking matters most, and our prescription leakage piece covers what that fragmentation costs a hospital over the life of one patient's ongoing care.

Sources

1. 1Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome — Human Reproduction, Oxford Academic
2. 2Recommendations from the 2023 international evidence-based guideline for PCOS — PubMed, National Institutes of Health
3. 3Effect of the combined oral contraceptive pill and/or metformin in PCOS: a systematic review with meta-analyses — PubMed, National Institutes of Health
4. 4Impact of combined hormonal contraceptives and metformin on metabolic syndrome in hyperandrogenic PCOS (COMET-PCOS trial) — PLOS Medicine
5. 5Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in PCOS — PMC, National Institutes of Health
6. 6World Health Organization: Polycystic ovary syndrome fact sheet — World Health Organization

This article is for informational purposes for clinicians and hospital administrators and is not a substitute for professional medical advice. Drug choice and sequencing must follow individual patient assessment and current guideline recommendations from a qualified physician.